Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/426—1,3-Thiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2009—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• the invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to achieving efficacious doses of orally administered doses docetaxel whilst controlling sided effects allowing for an extended use.
• Treatments of cancers involve a wide range of treatment. Treatments include i.a. surgery, radiation therapy, chemotherapy, immunotherapy and cell therapy. Often, cancer treatments include a combination of different modes of treatments, comprising combinations of different therapeutic agents.
• docetaxel a taxane
• Docetaxel is a cytotoxic agent, its main mode of action is understood to involve interference with microtubule assembly and disassembly, resulting in inhibiting mitotic cell division.
• the recommended dosage is a three-weekly intravenous administration, with a dose in the range of 75-100 mg / m2 of body surface area.
• Docetaxel is used in the treatment of a variety of cancers, which include breast, lung, prostate, gastric, head and neck, and ovarian cancer. While having the potential to benefit patients, improving life expectancy and quality of life, the use of docetaxel comes along with significant side effects. Typical side effects include i.a. neutropenia, a high risk of infections, thrombocytenia, anemia, alopecia, fluid retention, diarrhoea, nail toxicity, peripheral sensory neurotoxicity and infusion related reactions. Hence, the recommended mode of use involves a restricted number of cycles, usually 4-6 cycles, of docetaxel. In addition, standard premedication with high dose dexamethasone is needed every cycle.
• the current invention provides for a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.
• the current invention also provides for a method for reducing side effects of the treatment of a cancer in a patient, wherein said method comprises the administration of docetaxel, wherein said docetaxel is administered orally, controlling side effects by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.
• Reducing side effects and controlling side effects is of importance in general when using docetaxel.
• reducing or controlling side effects now allows for an extended use of docetaxel. This may be of importance for combination therapies, in which combinations of anticancer treatments are combined e.g. to durably maintain control of a cancer for extended periods.
• a CYP3A inhibitor such as ritonavir
• FIG 1 a plot is shown presenting AUC (average AUCs in h*ng/mL by dose level) of ritonavir (RTV) to ModraDoc006 (docetaxel). It shows that exposure of Modrodoc006 appears to be highly correlated to overall Ritonavir AUC (and dose).
• FIG 2A a plot is shown indicating similar or moderately higher levels of docetaxel AUC are obtained in patients as compared with IV.
• FIG 2B a plot is shown with the AUC of ritonavir.
• Figures 4, 5 A, 5B and 6 represent updates of Figures 1, 2 A, 2B, and 3, respectively.
• FIG 4 a plot is shown presenting AUC (average AUCs in h*ng/mL by dose level) of ritonavir (RTV) to ModraDoc006 (docetaxel). It shows that exposure of Modrodoc006 appears to be highly correlated to overall Ritonavir AUC (and dose).
• FIG 5 A a plot is shown indicating similar or moderately higher levels of docetaxel AUC are obtained in patients with ModraDoc006/r as compared with IV.
• 55% (1820/3300) represents the ratio of AUCs for IV docetaxel in mCPRC patients vs other tumors (De Vries Schultink et al,“Neutropenia and docetaxel exposure in metastatic castration- resistant prostate cancer patients: A meta- analysis and evaluation of a clinical cohort”, Cancer Medicine, February 2019).
• PSA state specific antigen
• FIG 8 a plot is shown of the number of treatment cycles (with a maximum of 30) in a multicenter clinical phase IB study in mCRPC (M17DOC) of evaluable patients. Patients were scored, as PSA progression (black bars); PSA equal to baseline or decline ( ⁇ 50%) (dark grey bars); PSA response (decline > 50%) (medium grey bars); clinical response (pain reduction) up to the maximum treatment period permitted in the protocol of 30 weeks (light grey bars).
• FIG 9 a plot is shown of best responders in a multicenter phase II
• mBC HER2- metastatic breast cancer
• N18DMB HER2- metastatic breast cancer
• a plot is shown of the total number of cycles in in a multicenter phase IIA study in HER2- metastatic breast cancer (mBC) (N18DMB) of 12 patients evaluable for safety evaluation. Patients scores were also indicated as having progression disease (PD) (black bars); Stable disease (SD) (dark grey bars); partial response (PR) (medium grey bars); or non evaluable (NE) (light grey bars). Patients indicated with a star have treatment ongoing.
• PD progression disease
• SD Stable disease
• PR partial response
• NE non evaluable
• the present invention provides for a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.
• the standard route of administration of docetaxel currently in use in the clinic involves intravenous administration of docetaxel. As the intravenous
• the present invention also provides for a method for reducing side effects of the treatment of a cancer in a patient, wherein said method comprises the administration of docetaxel, wherein said docetaxel is administered orally, controlling i.a. side effects by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.
• peak plasma levels are defined as the maximum concentration of a compound that can be measured in blood plasma obtained from a patient after administration of a pharmaceutical composition. Usually, peak plasma levels can be measured shortly after administration, but depending on the route of administration and the composition of the pharmaceutical composition there may be a lag between the time of administration and peak plasma levels measured. In intravenous
• the peak level can be measured e.g. at the end of the infusion.
• the time point at which the peak level occurs after oral administration may vary.
• the peak level may occur about 2-12 hours, e.g. 4 hours, after an oral administration.
• Plasma levels of docetaxel can be measured by methods know in the art (Hendrikx et al. J. Chrom. B, 2011), which may include liquid chromatography and mass spectrometry methods, such as e.g.
• Plasma is a blood component, it is understood that instead of measuring docetaxel in blood plasma, one can also determine levels of docetaxel in whole blood or in serum. Measurements of docetaxel, e.g. peak levels and area under the plasma concentration-time curve, in short area under the curve (AUC), herein are defined relative to (blood) plasma but can easily be recalculated to corresponding peak levels in whole blood or serum. In any case, high peak plasma levels that are to be avoided can be defined as docetaxel peak plasma levels of 3000 ng /mL or higher.
• the docetaxel peak plasma level in oral administration is at most 2500 ng/mL, preferably at most 2000 ng /mL, more preferably at most 1500 ng/mL most preferably the peak plasma level in oral administration is at most 1000 or even 500 ng/mL.
• an effective plasma level means a plasma concentration as measured in a subject that provides the specific pharmacological effect of docetaxel in a subject, i.e. eradicating cancer cells.
• An effective plasma level herein is defined as an area under the curve (AUC) as determined in the first 48 hours after the administration of docetaxel, wherein the AUC is within the range of 250 - 2500 ng-h/mL. Preferably the AUC is in the range of 750 - 2500 ng-h/mL.
• the AUC is at least 400 ng-h/mL, at least 500 ng-h/mL, more preferably at least 600 ng-h/mL, at least 1000 ng-h/mL, more preferably at least 1200 ng-h/mL.
• the AUC is at most 2500 ng-h/mL, more preferably at most 2250 ng-h/mL, more preferably at most 2000 ng-h/mL, at most 1800 ng-h/mL, at most 1700 ng-h/mL, more preferably at most 1500 ng-h/mL.
• the AUC may more preferably be within the range of 800 - 1400 ng-h/mL.
• the area under the curve (AUC; ng-h/mL) is determined in the first 48 hours after the administration of docetaxel, during which the docetaxel concentration in blood plasma can be measured at several timepoints, and the surface of the area under the curve can be calculated from the plotted values.
• AUC area under the curve
• AUC area under the curve
• docetaxel with reference to docetaxel are used interchangeably and refer to the area under the curve in the first 48 hours (ng-h/mL) after the administration of docetaxel.
• Eradicating cancer cells is understood to comprise the killing of cancer cells such that e.g. in case of a solid tumor, the growth of the solid tumor is reduced as compared with the growth of a tumor not having an effective plasma level of docetaxel present.
• the growth of a tumor may be reduced to such an extent that a tumor may be eradicated as well. It is emphasized that an effective plasma level may not always be effective in treating the conditions described herein in all subjects, even though such is deemed to be therapeutically effective by those of skill in the art.
• Neutropenia is an abnormally low concentration of neutrophils in the blood.
• Neutropenia is usually diagnosed by determining the absolute neutrophil count in the blood.
• a healthy range of neutrophil count in the blood can be defined as having 1500 - 4000 cells per microliter of blood.
• Neutropenia may be diagnosed when the level of neutrophils is below 1500 cells per microliter of blood.
• Assays to determine neutrophil counts are widely available as part of e.g. a complete blood count analysis as part of routine laboratory testing. Accordingly, in the current invention, the incidence of neutropenia is significantly reduced in the patient population while concomitantly providing for an effective treatment of the cancer in patients.
• the side effect neutropenia is controlled or reduced.
• Other side effects that may be controlled or reduced are thrombocytopenia, neuropathy, alopecia, fluid retention, neurotoxicity, and/or nail toxicity.
• docetaxel infusion- related reactions due to e.g. excipients (i.a. Tween-80, ethanol) used in intravenous formulations of docetaxel.
• excipients i.a. Tween-80, ethanol
• Corticosteroids such as dexamethasone
• toxicity that may be associated with (long-term) treatment with corticosteroids may be avoided as well.
• the oral administration of docetaxel to a subject includes any route through the mouth of introducing or delivering to a subject the agent to perform its intended function.
• Suitable pharmaceutical compositions for oral administration includes liquids, tablets or capsules.
• Capsules and tablets may have an enteric coating, such that docetaxel is released from the capsules or tablets in the intestine.
• Capsules and tablets may be formulated in an extended release formulation such that docetaxel is released over an extended period, e.g. several hours or more, e.g. during the time spend in the intestinal tract. Tablets and capsules may thus be formulated such that the agent is released therefrom gradually. Tablets and capsules may be formulated such that the agent is released in the stomach or intestine.
• Tablets and capsules may be formulated such that the agent is released in the stomach and intestine. Administration includes self-administration and the administration by another.
• Pharmaceutical compositions of this invention may comprise docetaxel, or pharmaceutically acceptable salts and esters thereof, and/or a CYP3A inhibitor, such as ritonavir, (or pharmaceutically acceptable salts and esters thereof) together with any pharmaceutically acceptable carrier, adjuvant or vehicle.
• Suitable preparations and/or pharmaceutical compositions for oral administrations include formulations as described in W02009027644, W02010020799 and Moes et al. Drug Deliv. Transl. Res. 2013) which are incorporated herein in its entirety by reference. Any suitable preparation for oral administration can be contemplated.
• the current invention may not be restricted to oral administration of docetaxel. Any administration of docetaxel via the gastrointestinal tract may be contemplated. Hence, enteral administration can be contemplated herein instead of oral administration. Preferably, enteral administration is in the form of capsules, tablets, and suppositories. Docetaxel administration via a suppository may be advantageous, as bioavailability may be improved as compared with oral administration. This is because with oral administration, after passing the stomach and intestine, docetaxel is delivered to the liver via the portal vein. By enteral administration, the barriers that metabolize docetaxel in the first -pass may be avoided. Any enteral administration may suffice, as long as peak levels are avoided and effective plasma levels are obtained, as defined herein.
• cytochrome P450 represents a main oxidative drug metabolizing enzyme system.
• Cytochrome P450 (CYP) iso-enzymes in particular CYP3A4, but also CYP3A5, are highly expressed in the liver and intestines. Intestinal extraction and metabolism of docetaxel by this enzyme system plays an important role in limiting oral bioavailability.
• CYP3A4 and/or CYP3A5 enzymes are highly expressed in the liver and intestines. Intestinal extraction and metabolism of docetaxel by this enzyme system plays an important role in limiting oral bioavailability.
• As part of the metabolic route transporters also play a role.
• the compound is provided as a substrate to the CYP3A4 and/or CYP3A5 enzymes.
• the P-glycoprotein plays a role in the metabolic route and transport of docetaxel.
• any compound that may have an effect on the metabolic route of docetaxel to thereby inhibit metabolizing docetaxel may be considered a suitable CYP3A inhibitor.
• Such compounds may e.g. have an effect on CYP3A4 and/or CYP3A5, and on P-glycoprotein (Er-jiaWang et al, Chem. Res. Toxicol. 2001 ; Wacher et al., Mol Care.
• Suitable CYP3A inhibitors may thus have an effect on both CYP3A4 (and CYP3A5) and P- glycoprotein. Suitable CYP3A inhibitors may thus have an effect on CYP3A4 and/or CYP3A5.
• Suitable CYP3A inhibitors may have an effect on P-glycoprotein.
• a CYP3A inhibitor is defined herein as a compound capable of reducing CYP3A4 and CYP3A5 metabolism in the cell.
• Said compound preferably is a pharmaceutical compound.
• a CYP3A inhibitor is selected that inhibits CYP3A4, such as e.g. ritonavir.
• Ritonavir inhibits CYP3A5 and P-glycoprotein as well. Highly preferred is selective inhibition of CYP3A4.
• the plasma levels of docetaxel are at least partially controlled by administering a CYP3A inhibitor.
• a CYP3A inhibitor accordingly assisting in transporting docetaxel from the stomach and/or intestine to the bloodstream, by reducing and/or inhibiting CYP3A4 and/or CYP3A5 activity in the cell.
• the use of a CYP3A inhibitor can thus provide for increased bioavailability of docetaxel. Such bioavailability may be increased, while not substantially increasing the peak levels of docetaxel.
• a CYP3A inhibitor allows for the use of a lower dosage of oral docetaxel as effective plasma levels of docetaxel can be increased as compared with not using a CYP3A inhibitor.
• the use of a CYP3A inhibitor allows for the use of less frequent dosing of oral docetaxel, as effective plasma levels with the area under the curve as defined herein can be more efficiently obtained as compared with not using a CYP3A inhibitor.
• the plasma levels of docetaxel are at least partially controlled by administering a CYP3A inhibitor.
• the oral administration of docetaxel is to be combined with the use of a CYP3A inhibitor.
• Any CYP3A inhibitor may suffice, e.g. a suitable CYP3A inhibitor may be potent CYP3A inhibitors selected from the group consisting of boceprevir, claritromycine, erytromycine, indinavir, itraconazole, ketoconazole, posaconazole, ritonavir, saquinavir en voriconazole.
• a CYP3A inhibitor is used that has the least side effects.
• the CYP3A inhibitor that is combined with oral administration of docetaxel is ritonavir.
• the CYP3A inhibitor for use in a combination therapy in accordance with the invention comprises ritonavir administered in a dosage of 100 ng or 200 ng, or an equivalent dosage of another suitable CYP3A inhibitor.
• One can easily establish the suitable dosage for any other suitable inhibitor as one can compare the effect of the CYP3A inhibitor ritonavir in a subject and select another CYP3A inhibitor and establish the dosage thereof that obtains the same effect.
• the effect being defined as the effect on docetaxel plasma levels (AUC) and/or peak plasma levels as obtained with the dosage of ritonavir used.
• any additional use of compounds, including foods and further pharmaceuticals, that may have an impact on CYP3A activity are preferably avoided as such foods may have an effect on the levels of docetaxel achieved in the plasma of subjects being treated.
• the further use of inhibitors of CYP3A by the subjects receiving treatment needs to be avoided as this may result in too high peak levels of docetaxel and/or too high area under the curves.
• further inhibitors that are preferably avoided are e.g. HIV
• Antivirals indinavir, nelfinavir and saquinavir; Anti-microbial agents: clarithromycin, itraconazole, ketoconazole, nefazodone, telithromycin, erythromycin, fluconazole, chloramphenicol, ciprofloxacin, norfloxacin and voriconazole; Cardiac agents: verapamil, diltiazem, cimetidine and miodarone; other agents such as fluvoxamine; and also foods, such as star fruit and grapefruit juice.
• the use of compounds, including foods and further pharmaceuticals, that may induce CYP3A activity in the subjects receiving treatment is preferably avoided as well, as such use may result in too high peak levels of docetaxel in plasma.
• Inducers of CYP3A that are preferably avoided are: HIV Antivirals: efavirenz and nevirapine; Other agents such as : barbiturates, carbamazepine, modafinil, nevirapine, oxcarbazepine, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampicin and also St. John's wort.
• said CYP3A inhibitor is simultaneously administered with docetaxel.
• simultaneous administration can comprise separate administrations, e.g. in separate pharmaceutical preparations.
• one pharmaceutical preparation suitable for oral administration comprising docetaxel and another pharmaceutical preparation comprising the CYP3A inhibitor, such as ritonavir.
• the pharmaceutical preparation comprising ritonavir preferably also being orally administered.
• simultaneous administration can comprise one pharmaceutical preparation comprising both docetaxel and the CYP3A inhibitor, such as ritonavir.
• Docetaxel and the CYP3A inhibitor can also be administered separately from each other.
• the CYP3A inhibitor is preferably administered before docetaxel, and, more preferably, within approximately 60 minutes before docetaxel is administered.
• administration of the docetaxel or CYP3A inhibitor within e.g. approximately 20 minutes, more preferably within 15 minutes, more preferably within 10 minutes, even more preferably within 5 minutes, most preferably within 2 minutes of the CYP3A inhibitor or docetaxel.
• the CYP3A inhibitor is preferably orally administered simultaneously with administering oral docetaxel as this provides for optimal compliance in self-administration by subjects receiving treatment.
• said treatment of cancer comprises an extended use of more than 18 weeks.
• the standard intravenous route of administration and standard use of docetaxel do not allow to recommend extended use because of the severe side effects and increasing toxicity associated with multiple administrations.
• the methods of treatment now allow for a use that extends for longer periods.
• the methods of the invention allow for an extended use beyond 30 weeks, said methods comprising controlling or reducing the side effects associated with the use of docetaxel while maintaining an effective plasma level of docetaxel that eradicates tumor cells.
• the methods of the invention allow for an extended use of at least 30 weeks of treatment. Such use allowing for an extended use of a year or more.
• the ranges within which docetaxel is to be administered in the methods and uses of the invention may allow for both effective tumor cell eradication and controlled or reduced side effects of docetaxel.
• the effective plasma level may be regarded to represent the range within which docetaxel can effectively eradicate cancer cells.
• the peak plasma levels may be regarded to represent the upper limit within which side effects of docetaxel can be controlled or reduced.
• any suitable pharmaceutical acceptable formulation and/or dosage regimen that operates within this range may be contemplated and is to provide the advantageous tumor cell eradication and side effect control or reduction of docetaxel as described herein and also allows for an extended use, as is not conceived as possible with the standard licensed treatments of intravenously administered docetaxel.
• administrations of docetaxel can be on a tri daily, bi-daily or daily basis, every two days, weekly, every two weeks, every three weeks or any other suitable dosing interval. Combinations of these dosage regimens can also be used, for example, the composition can be for bi- daily administration once every week or every two or three weeks.
• docetaxel can be administered on a bi-daily basis once a week. The weekly dose is split so that a subject takes, for example, a first dose in the morning and the second dose in the evening once a week. This has the effect of decreasing the peak levels of the drug in plasma which may aid reducing side effects. It also may increase the time of systemic exposure of the drug.
• the methods, or uses, in accordance with the invention comprise docetaxel being administered weekly.
• Docetaxel may also be administered bidaily weekly, meaning that on one day every week, docetaxel is administered twice, e.g. within an 8- 16 hours interval.
• the dosing interval and/or dosage of docetaxel and the CYP3A inhibitor, such as ritonavir is selected that allows to provide preventing peak plasma levels thereby controlling or reducing side effects while maintaining effective plasma levels to eradicate tumor cells, such dosing interval and/or dosage may be contemplated.
• docetaxel is administered at a dosage of at least 10 mg per dosage administration, as such a dosage already can provide for effective plasma levels of docetaxel to eradicate tumor cells, while controlling or reducing side effects of docetaxel in patients.
• said dosage is at least 20 mg per dosage administration.
• docetaxel is administered preferably simultaneously with a CYP3A inhibitor, such as ritonavir.
• ritonavir is administered simultaneously at a dosage of at least 100 mg.
• ritonavir is simultaneously administered with docetaxel at each moment of dosing comprising the administration at least 10 mg of docetaxel and at least 100 mg of ritonavir.
• an administration may be at a weekly schedule or a bidaily weekly schedule.
• a bidaily weekly schedule as described above at each moment of administration comprises the administration of at least 10 mg of docetaxel, or the administration of at least 10 mg of docetaxel and at least 100 mg of ritonavir.
• a bidaily weekly schedule is provided for the treatment of cancer, wherein docetaxel is administered on one day a first administration at a dosage of 30 mg docetaxel with 100 mg ritonavir and a second administration at a dosage of 20 mg docetaxel with 100 mg ritonavir.
• a bidaily weekly schedule is provided for the treatment of cancer, wherein docetaxel is administered on one day a first administration at a dosage of 30 mg docetaxel with 200 mg ritonavir and a second administration at a dosage of 20 mg docetaxel with 100 mg ritonavir.
• a bidaily weekly schedule for the treatment of cancer, wherein docetaxel is administered on one day a first administration at a dosage of 30 mg docetaxel with 200 mg ritonavir and a second administration at a dosage of 20 mg docetaxel with 200 mg ritonavir.
• a bidaily weekly schedule is provided for the treatment of cancer, wherein docetaxel is administered on one day a first administration at a dosage of 20 mg docetaxel with 200 mg ritonavir and a second administration at a dosage of 20 mg docetaxel with 200 mg ritonavir.
• a bidaily weekly schedule is provided for the treatment of cancer, wherein docetaxel is administered on one day a first administration at a dosage of 20 mg docetaxel with 100 mg ritonavir and a second administration at a dosage of 20 mg docetaxel with 100 mg ritonavir.
• a bidaily weekly schedule for the treatment of cancer, wherein docetaxel is administered on one day a first administration at a dosage of 20 mg docetaxel with 200 mg ritonavir and a second administration at a dosage of 20 mg docetaxel with 100 mg ritonavir.
• the cancer in another embodiment, in a method in accordance with the invention is a solid tumor.
• the cancer being treated may be the same as currently prescribed for intravenous administrations of docetaxel.
• the methods include treatments of cancer wherein the cancer is a solid tumor selected from the group consisting of gastric cancer, breast cancer, head and neck cancer, lung cancer and prostate cancer.
• the current invention provides for a combination of a CYP3A inhibitor and docetaxel for use in a medical treatment of a cancer, wherein said use comprises oral administration of docetaxel, said use comprises preventing peak plasma levels of docetaxel that induce side effects whilst maintaining plasma levels of docetaxel that eradicate tumor cells.
• the current invention provides for docetaxel for use in a combination therapy in the treatment of cancer, wherein said docetaxel is to be administered in combination with a CYP3A inhibitor and wherein said use comprises oral administration of docetaxel, and wherein said use comprises preventing peak plasma levels of docetaxel that induce side effects whilst maintaining plasma levels of docetaxel that eradicate tumor cells.
• the invention provides for a CYP3A inhibitor for use in a combination therapy in the treatment of cancer, wherein said CYP3A inhibitor is to be administered in combination with docetaxel and wherein docetaxel is administered orally, said use comprising preventing peak plasma levels of docetaxel that induce side effects whilst maintaining plasma levels of docetaxel that eradicate tumor cells.
• Said CYP3A inhibitor in these embodiments is preferably ritonavir.
• said uses as described above comprises peak plasma levels of docetaxel of at most 2500 ng/mL. Said upper limit provides plasma levels that are not associated with side effects. Said uses as described above preferably comprise effective plasma levels of docetaxel in the range of an AUC in between 800 and 2000 ng-h/mL.
• said uses as described above preferably comprise effective plasma levels of docetaxel in the range of an AUC in between 1000 and 2000 ng-h/mL.
• Said uses preferably comprise an extended use of more than 30 weeks.
• Said uses preferably comprise the treatments of cancer wherein the cancer is a solid tumor.
• Said uses preferably comprise a cancer wherein the cancer is a solid tumor selected from the group consisting of gastric cancer, breast cancer, head and neck cancer, lung cancer and prostate cancer.
• the current invention also provides for a kit comprising a pharmaceutical composition for oral administration comprising docetaxel and a pharmaceutical composition comprising a CYP3A inhibitor, wherein said kit is for extended use in the treatment of cancer.
• a kit is provided comprising a pharmaceutical composition for oral administration comprising docetaxel and a pharmaceutical composition comprising a CYP3A inhibitor, wherein said kit is for uses and methods as described herein.
• Modradoc006 is a spray-dried solid dispersion formulation of docetaxel pressed into tablets
• the formulation excipients are polyvinyl pyrrolidone K30, sodium dodecyl sulphate, lactose monohydrate, croscarmellose, silica colloidalis anhydrica and magnesium stearate. All excipients are included in the FDA guide for inactive compounds (oral capsules and tablets).
• Ritonavir is commercially available as 100 mg tablets for oral consumption (Norvir®). This tablet has been granted approval by the European Commission in 2010.
• a combined assay for the determination of docetaxel and ritonavir in human plasma is described.
• the drugs were extracted from 200 pL human plasma using liquid-liquid extraction with tertiary- butylmethylether, followed by high performance liquid chromatography analysis using 10 mM ammonium hydroxide pH 10:methanol (3:7, v/v) as mobile phase. Chromatographic separation was obtained using a Zorbax Extend C(18) column. Labelled analogues of the analytes are used as internal standards. For detection, positive ionization electrospray tandem mass spectrometry was used. Method development including optimisation of the mass transitions and response, mobile phase optimisation and column selection are discussed.
• the method was validated according to FDA guidelines and the principles of Good Laboratory Practice (GLP).
• GLP Good Laboratory Practice
• the validated range was 0.5-500 ng/mL for docetaxel and 2-2000 ng/mL for ritonavir.
• quadratic calibration curves were used (r(2)>0.99).
• the total runtime of the method is 9 min and the assay combines analytes with differences in ionisation and desired concentration range.
• Inter-assay accuracy and precision were tested at four concentration levels and were within 10% and less than 10%, respectively, for all analytes.
• Carry-over was less than 6% and endogenous interferences or interferences between analytes and internal standards were less than 20% of the response at the lower limit of quantification level.
• the matrix factor and recovery were determined at low, mid and high concentration levels.
• the matrix factor was around 1 for all analytes and total recovery between 77.5 and 104%.
• Stability was investigated in stock solutions, human plasma, dry extracts, final extracts and during 3 freeze/thaw cycles. The described method was successfully applied in clinical studies with oral administration of docetaxel in combination with ritonavir.
• the docetaxel exposure in these patients was:
• NIOBOM phase I trial
• the docetaxel exposure in these patients was: AUC0-48h 1224+620 h.ng/mL
• a weekly administration of docetaxel (35 mg/m2) as a 0.5 h intravenous infusion gives the following AUC and CMAX -values.
• Intravenous (35 mg/m2 in 0.5 h) docetaxel gives a ten-fold higher CMAX than oral docetaxel treatment (ModraDoc006/r 30-20 / 100-100) which may explain higher toxicity for the intravenous treatment;
• This treatment (denoted as ModraDoc006/r 30-20/100-100) is given on one day, once every week.
• phase I target 1100
• phase IB/IIA mCRPC 500 45 30-20 / 200-200 (phase IB/IIA mCRPC) 2000 165
• phase IB/IIA mCRPC phase IB/IIA mCRPC 1100 135
• ModraDoc006 an oral docetaxel formulation was combined with ritonavir (ModraDoc006/r), in metastasized castration-resistant prostate cancer (mCRPC).
• mCRPC dosed in a bi-daily once weekly (BIDW) dosing schedule at 4 dose levels (see table below).
• the docetaxel exposure was in cycle 1 : median AUC from 0-48h + SD 419+158 h.ng/mL and CMAX 53+21 ng/mL.
• phase IB/IIA mCRPC 1500
• phase IB/IIA mCRPC 20-20 / 200- 100 (phase IB/IIA mCRPC) 420 50
• PSA prostate specific antigen
• SD Stable disease
• non CR non complete response
• non PD non progressive disease
• PD progressive disease
• NE non evaluable
• PR partial response
• PSA response PSA decline >50%) was observed, of which 5 were confirmed by a second measurement after 6 weeks.
• PSA declined ⁇ 50% or remained equal to baseline.
• PSA increase was observed.
• PSA decline ⁇ 50% in one patient and PSA increase in another patient, noticeable clinical response with pain reduction was achieved during the maximum treatment duration of 30 weeks.
• ModraDoc006/r 30- 20 / 200-100 is a preferred initial dose to be further tested in mCRPC, given it demonstrated the ability to achieve exposure levels of docetaxel (as measured by AUC) which were higher than achieved with IV docetaxel, while also having acceptable toxicity.
• ModraDoc006/r 20- 20 / 200-100 may be another preferred dose, or preferered initial dose, in mCRPC. Phase PA study in breast cancer
• Tumor measurements represent changes in tumor size over time as measured by CT scan, with the initial value being baseline.
• PD progressive disease

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Inorganic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (16)

Applications Claiming Priority (2)

Related Child Applications (3)

Publications (1)

Family

ID=64901394

Family Applications (1)

Country Status (14)

Cited By (1)

Families Citing this family (2)

Citations (2)

Family Cites Families (5)

• 2019
  • 2019-12-18 PE PE2021001049A patent/PE20220250A1/es unknown
  • 2019-12-18 KR KR1020217022968A patent/KR20220002860A/ko not_active Ceased
  • 2019-12-18 BR BR112021012255-9A patent/BR112021012255A2/pt not_active Application Discontinuation
  • 2019-12-18 MX MX2021007478A patent/MX2021007478A/es unknown
  • 2019-12-18 CN CN201980090615.9A patent/CN113543781A/zh active Pending
  • 2019-12-18 US US17/416,977 patent/US20220079910A1/en not_active Abandoned
  • 2019-12-18 JP JP2021536409A patent/JP2022515249A/ja active Pending
  • 2019-12-18 CA CA3124316A patent/CA3124316C/en active Active
  • 2019-12-18 WO PCT/EP2019/086124 patent/WO2020127606A1/en not_active Ceased
  • 2019-12-18 EP EP19828724.5A patent/EP3897610B1/en active Active
  • 2019-12-18 AU AU2019410060A patent/AU2019410060A1/en not_active Abandoned
  • 2019-12-18 ES ES19828724T patent/ES3026709T3/es active Active
• 2021
  • 2021-06-18 CL CL2021001638A patent/CL2021001638A1/es unknown
  • 2021-06-18 MX MX2025008270A patent/MX2025008270A/es unknown
  • 2021-06-20 IL IL284213A patent/IL284213A/en unknown
• 2022
  • 2022-06-06 US US17/833,745 patent/US11571408B2/en active Active
• 2023
  • 2023-05-01 JP JP2023075517A patent/JP2023102787A/ja active Pending
  • 2023-07-14 AU AU2023204682A patent/AU2023204682A1/en not_active Abandoned
• 2025
  • 2025-02-28 US US19/066,854 patent/US20250312305A1/en active Pending
  • 2025-03-24 JP JP2025049089A patent/JP2025094189A/ja active Pending

Patent Citations (2)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events